ArcticZymes Technologies — AGM Information 2016

Feb 11, 2016

Biotec Pharmacon: Capital Markets Day 2016

Biotec Pharmacon: Capital Markets Day 2016

(Tromsø, 11 February 2016) Biotec Pharmacon ASA ("Biotec", OSE: BIOTEC)

announces today the company´s 2018 targets and long-term strategic update at

Biotec´s Capital Markets Day 2016 (CMD). The company targets NOK 100 million in

revenues, a cash positive operation and a strong product pipeline by 2018.

Commercialisation of Woulgan® in key markets is at the very core to fulfil the

company's long-term ambitions. Biotec believes that the Woulgan® product

platform has an opportunity of at least USD 100 million in-market revenue

potential.

- Biotec has a strong platform for creating shareholder values towards 2018 and

beyond. We have

over the past years emerged into a commercially driven company. In 2016, Biotec

is a company dedicated to develop the commercial value of our key product

Woulgan®, strengthen ArcticZymes market position through long-term partnerships,

and product development based on our strong technology platforms, says Svein

Lien, Chief Executive Officer of Biotec.

At the company's Capital Markets Day 11 February 2016, Biotec will provide

investors, analysts and journalists with a long-term strategic update and the

following 2018 targets:

· Full commercialisation of Woulgan® in key markets

· NOK 100 million in group revenues

· A cash positive and fully funded operation

· A strong product pipeline

· Enhancing the value creation potential for ArcticZymes through organic

growth, partnerships and strategic opportunities

- Biotec BetaGlucans are currently working at full pace to position Woulgan®,

our premium priced product targeting "stalled wounds". This positioning

represents at least annual USD 100 million in-market sales opportunity for the

product platform. Short-term focus will be to position the gel product towards

the professional wound care market in the UK and the Nordics. To secure new

distribution agreements, establish key opinion leader support, obtain acceptable

reimbursements supported by health economic data, enter new markets through

clever roll-out of our product to key customers is at the heart of our

commercialisation strategy going forward, says Lien, and points to the Woulgan®

operational targets for 2016:

· Enter into a distribution agreement(s) for Woulgan® in Germany

· Finalise the UK reimbursement process in the high-end category of the market

· Drive sales in UK and the Nordic

· Continue to build the strong international sales support organisation

In parallel, Biotec BetaGlucans will develop existing and new supplier

agreements both within animal health and nutrition, in addition to explore

opportunities within the field of cancer.

- Biotec BetaGlucan's technology platform is one of the Company's key strengths

and strategic advantages. We have already obtained proof of concept with regards

to the spray and dressing formats of Woulgan®, which ultimately will broaden our

portfolio of new opportunities further, says Lien.

In the enzymes market, ArcticZymes has a strong product offering, valuable and

long-term relationships with key customers, and a solid position for future

growth.

- ArcticZymes has a unique value proposition. Through its existing product

portfolio, by developing novel enzymes and to further strengthen its

partnerships with large companies in molecular, diagnostic and adjacent markets,

ArcticZymes should be able to increase its market share going forward. In

addition, we expect the enzyme market to grow and develop structurally over the

next years, as the industry represents attractive opportunities for a wide array

of partners and companies in adjacent industries, says Lien.

Agenda for the day:

0830-0900         Q4 Presentation, Svein Lien (CEO)

Capital markets day agenda:

0900-0905         Introduction, Svein Lien (CEO)

0905-0925         Innate immunity and Woulgan® product development, Rolf Engstad

(CSO)

0925-0950         Woulgan® - wound care, Stuart Devine (VP Marketing)

0950-1000         Immunotherapy of Cancer, Rolf Engstad (CSO)

1000-1010         Q&A

1010-1045         ArcticZymes value proposition, Jethro Holter (Managing

Director)

1045-1055         Q&A

1055-1100         Closing remarks and outlook, Svein Lien (CEO)

The presentation material from Biotec's Capital Markets Day is enclosed and made

available on www.biotec.no. The presentations will be webcasted live and in

replay on www.biotec.no

For additional information,

Svein Lien, CEO, +47 922 89 323, svein.lien@biotec.no

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and

ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel

immunomodulating products, including Woulgan®, a premium priced product in the

advanced wound care market. ArcticZymes develops, produces and markets enzymes

of marine origin used in molecular DNA technologies and diagnostics,

representing growth markets where rapid technological developments are creating

a strong demand for new and improved enzymes.